Ziprasidone

Generic Name
Ziprasidone
Brand Names
Geodon, Zeldox
Drug Type
Small Molecule
Chemical Formula
C21H21ClN4OS
CAS Number
146939-27-7
Unique Ingredient Identifier
6UKA5VEJ6X
Background

Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior. These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers. Luckily, several treatment options for psychotic disorders have been ...

Indication

In its oral form, ziprasidone is approved for the treatment of schizophrenia, as monotherapy for acute treatment of manic or mixed episodes related to bipolar I disorder, and as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar I disorder. The injectable formulation is approved only for treatment of acute agitation in schizophre...

Associated Conditions
Acute Agitation, Agitation, Bipolar 1 Disorder, Psychosis, Schizophrenia, Treatment Resistant Major Depressive Disorder, Acute Manic episode, Acute Mixed manic depressive episode
Associated Therapies
-
Clinical Trials
Related News

Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone

First Posted Date
2007-10-03
Last Posted Date
2012-11-29
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
24
Registration Number
NCT00538642
Locations
🇺🇸

The University of Texas Health Science Center At San Antonio, San Antonio, Texas, United States

Glucose and Lipid Metabolism on Antipsychotic Medication

First Posted Date
2007-08-14
Last Posted Date
2019-10-02
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
96
Registration Number
NCT00515723
Locations
🇺🇸

Washington Univeristy School of Medicine, Saint Louis, Missouri, United States

🇺🇸

Washington University School of Medicine, Psychiatry Dept., Saint Louis, Missouri, United States

Adjunctive Ziprasidone in the Treatment of Bipolar I Depression

First Posted Date
2007-06-07
Last Posted Date
2021-03-10
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
298
Registration Number
NCT00483548
Locations
🇮🇳

Pfizer Investigational Site, Delhi, New Delhi, India

Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics

Phase 4
Completed
Conditions
Schizophrenia
Schizoaffective Disorder
Interventions
Drug: ziprasidone
First Posted Date
2007-04-10
Last Posted Date
2020-05-01
Lead Sponsor
Bronx Psychiatric Center
Target Recruit Count
40
Registration Number
NCT00458211
Locations
🇺🇸

Buffalo Psychiatric Center, Buffalo, New York, United States

🇺🇸

Bronx Psychiatric Center, Bronx, New York, United States

Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.

First Posted Date
2007-04-02
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
379
Registration Number
NCT00454883

Open-label Ziprasidone Study for Psychosis Treatment in Adolescents

First Posted Date
2007-01-15
Last Posted Date
2017-01-13
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
8
Registration Number
NCT00421954
Locations
🇺🇸

NYSPI, New York, New York, United States

Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)

Phase 4
Completed
Conditions
Schizophrenia
First Posted Date
2007-01-04
Last Posted Date
2009-10-26
Lead Sponsor
Pfizer
Target Recruit Count
18239
Registration Number
NCT00418171
Locations
🇺🇸

Pfizer Investigational Site, Whitehall, West Virginia, United States

Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone

Phase 4
Completed
Conditions
Schizophrenia
Schizoaffective Disorder
Interventions
Drug: ziprasidone
First Posted Date
2006-12-04
Last Posted Date
2021-03-29
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
255
Registration Number
NCT00406315
Locations
🇹🇷

Pfizer Investigational Site, Izmit, Turkey

Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder

Phase 2
Completed
Conditions
Schizophrenia
Schizoaffective Disorder
Interventions
Drug: Ziprasidone
First Posted Date
2006-11-02
Last Posted Date
2011-07-29
Lead Sponsor
Manhattan Psychiatric Center
Target Recruit Count
57
Registration Number
NCT00395031
Locations
🇺🇸

Manhattan Psychiatric Center, New York, New York, United States

Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder

First Posted Date
2006-09-11
Last Posted Date
2014-04-16
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
3
Registration Number
NCT00374543
Locations
🇺🇸

Center for Anxiety and Traumatic Stress Disorders at Massachusetts General Hospital, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy